Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sanofi, Alnylam Complete Research Phase of Rare Disease Alliance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/08/2019 | 01:32am EDT

By Nathan Allen

Sanofi said Monday that it has concluded the research-and-option phase of its rare-disease alliance with Alnylam Pharmaceuticals

Through the alliance, which was set up in 2014, the companies developed a treatment for patients with ATTR amyloidosis and are testing a molecule to treat hemophilia, Sanofi said.

In the new phase of the alliance Alnylam will proceed with another early-stage therapy for an undisclosed rare disease, taking it through to initial trials.

Sanofi said it will then be responsible for any further development of the therapy, paying royalties to Alnylam from global sales.

The two companies have amended their equity agreement, with France's Sanofi obtaining a release from its lock-up of trading in Alnylam's shares.

Write to Nathan Allen at nathan.allen@dowjones.com

Stocks mentioned in the article
ChangeLast1st jan.
ALNYLAM PHARMACEUTICALS, INC. -0.07% 82.14 Delayed Quote.12.66%
SANOFI 0.40% 77.31 Delayed Quote.2.48%
SANOFI 0.27% 77.36 Real-time Quote.1.85%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
08/20BAYER : Elanco to become No.2 in animal health with $7.6 billion Bayer deal
RE
08/20BAYER : Elanco to become No.2 in animal health with $7.6 billion Bayer deal
RE
08/16SANOFI AVENTIS : Board of directors meeting of Sanofi - Aventis Pakistan Limited
AQ
08/12REGENERON PHARMACEUTICALS : Two Experimental Ebola Drugs Reduce Mortality Rate
DJ
08/12United States Insulin Delivery Devices Market is Anticipated to Reach US$ 6 B..
AQ
08/12No-deal Brexit could deepen Europe's shortage of medicines - experts
RE
08/07SANOFI : DOH won't rush review on Dengvaxia
AQ
08/07REGENERON PHARMACEUTICALS : Dupixent Showed Positive Topline Results in Phase 3 ..
AQ
08/07REGENERON PHARMACEUTICALS : Dupixent Approved by European Commission for Adolesc..
AQ
08/07SANOFI : - Dupixent approved by European Commission for adolescents with moderat..
AQ
More news
Financials (EUR)
Sales 2019 36 243 M
EBIT 2019 9 446 M
Net income 2019 4 174 M
Debt 2019 14 643 M
Yield 2019 4,09%
P/E ratio 2019 25,2x
P/E ratio 2020 17,1x
EV / Sales2019 3,06x
EV / Sales2020 2,88x
Capitalization 96 324 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 87,32  €
Last Close Price 77,06  €
Spread / Highest target 29,8%
Spread / Average Target 13,3%
Spread / Lowest Target 2,52%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI1.85%106 825
JOHNSON & JOHNSON2.48%344 675
ROCHE HOLDING LTD.12.16%238 287
MERCK AND COMPANY12.09%219 296
NOVARTIS17.97%204 985
PFIZER-19.40%191 430